Oncology
HER2-Mutant Lung Cancer Just Moved Into First Line
FDA has expanded accelerated approval of sevabertinib to treatment-naive advanced HER2-mutant non-squamous NSCLC. The drug produced a 75% response rate. The real access gate is now the test.
CAR-T Starts Moving From Factory Medicine to In-Patient Engineering
AML’s Frontline Future Starts With Finding the Mutation Fast
Cancer Is Chaos. Patients Should Not Have to Become Their Own Operating System
Surviving Cancer Is Not the Same as Being Recovered
CAR-T Starts Moving From Factory Medicine to In-Patient Engineering
AML’s Frontline Future Starts With Finding the Mutation Fast
GIST Care Looks Beyond First-Generation KIT Control
Pancreatic Cancer Finally Gets a RAS Moment
GSK’s Nuvalent Deal Turns Lung Cancer Precision Into a $10.6 Billion Access Race
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.
Diseases in Oncology
Explore disease data and country profiles on the IPM Alliance platform.
Explore diseases